A device developed by MGH investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology. In their report appearing in PNAS Early Edition, the researchers describe a smartphone-based device that uses the kind of technology used to make holograms to collect detailed microscopic images for digital analysis of the molecular composition of cells and tissues.
“The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care,” says Cesar Castro, MD, of the MGH Cancer Center and Center for Systems Biology, co-lead author of the report. “The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients; and we believe the platform we have developed provides essential features at an extraordinary low cost.”
The device the team has developed – called the D3 (digital diffraction diagnosis) system – features an imaging module with a battery-powered LED light clipped onto a standard smartphone that records high-resolution imaging data with its camera. With a much greater field of view than traditional microscopy, the D3 system is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. The data can then be transmitted for analysis to a remote graphic-processing server via a secure, encrypted cloud service, and the results rapidly returned to the point of care.
For molecular analysis of tumors, a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules and loaded into the D3 imaging module. After the image is recorded and data transmitted to the server, the presence of specific molecules is detected by analyzing the diffraction patterns generated by the microbeads. The use of variously sized or coated beads may offer unique diffraction signatures to facilitate detection. A numerical algorithm developed by the research team for the D3 platform is capable of distinguishing cells from beads and of analyzing as much as 10 MB of data in less than nine hundredths of a second.
A pilot test of the system with cancer cell lines detected the presence of tumor proteins with an accuracy matching that of the current gold standard for molecular profiling, and the larger field of view enabled simultaneous analysis of more than 100,000 cells at a time. The investigators then conducted analysis of cervical biopsy samples from 25 women with abnormal PAP smears – samples collected along with those used for clinical diagnosis – using microbeads tagged with antibodies against three published markers of cervical cancer. Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching those of conventional pathologic analysis.
Read more: Smartphone-based device could provide rapid, low-cost molecular tumor diagnosis
The Latest on: Molecular tumor diagnosis
[google_news title=”” keyword=”Molecular tumor diagnosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Molecular tumor diagnosis
- Northwell opens $3.2M Molecular Diagnostics Laboratoryon May 7, 2024 at 9:22 am
The Northwell Health Cancer Institute and its Center for Genomic Medicine announced the opening of Long Island’s first clinical Molecular Diagnostics Laboratory (MDL), a $3.2 mi ...
- Cancer Diagnostics Market Size to Reach USD 204.8 Billion By 2032, at 6.6% CAGR: Dimension Market Researchon May 7, 2024 at 6:38 am
The global cancer diagnostics market is engaged in diverse activities, products, and services for detecting, diagnosing, and monitoring cancer, utilizing technologies like molecular diagnostics ... as ...
- How imaging techniques revolutionise gall bladder cancer diagnosison May 6, 2024 at 10:09 pm
Gall bladder cancer (GBC) presents notable obstacles when it comes to detection and diagnosis. This is especially true in this new molecular based era where precise and accurate diagnosis is crucial.
- New Statistical Report Reveals Primary Brain and Central Nervous System Tumors as Second Most Common Cancer Type in Adolescents and Young Adultson May 6, 2024 at 9:30 pm
Over 90 percent survived for at least five years, with approximately 208,620 AYAs living with a history of brain or other CNS tumor diagnosis in 2024 ... current tumor classifications based on recent ...
- New Biomarkers Improve Renal Cancer Diagnosison May 6, 2024 at 4:36 pm
Despite having different molecular make-ups, non-ccRCCs are treated with the standard of care devised for the common form, affecting treatment outcomes. Differential diagnosis of non-ccRCC tumors can ...
- Diagnosed With Non-Small Cell Lung Cancer? Here’s Why You Need Biomarker Testingon May 6, 2024 at 11:46 am
Biomarker tests can help your doctor learn more about the type of lung cancer you have and the best way to treat it.
- Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—eventually—treatmenton May 5, 2024 at 5:00 pm
A new study led by University of Michigan Health Rogel Cancer Center researchers identifies novel biomarkers in renal cell carcinomas. The researchers’ integrative analysis of comprehensive ...
- Exploring molecular landscapes of cancer in Hispanic/Latin American patientson May 3, 2024 at 10:20 pm
A new editorial paper was published in Oncoscience (Volume 11) on April 22, 2024, entitled, "Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for ...
- Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patientson May 3, 2024 at 12:11 pm
this editorial underscores the complex molecular diagnosis landscape of cancer in the [Latin American] population.” “This disparity can be attributed to several factors, including smoking habits, diet ...
- How endometrial cancer is being treated using molecular profilingon May 2, 2024 at 10:13 pm
Dr. Ebony Hoskins, a board-certified gynecologic oncologist at MedStar Washington Hospital Center, said data showed combining immunotherapy with chemotherapy had improved progression-free survival.
via Bing News